Positrigo is a medical imaging company that has built NeuroLF®, an ultra-compact PET scanner designed specifically for brain imaging. Traditional PET machines are large and costly; Positrigo’s innovation is a helmet-like dedicated brain PET that can be used in smaller clinics or even mobile settings, making advanced neuroimaging more accessible. In 2024, NeuroLF obtained FDA clearance, validating its safety and effectiveness in diagnosing and monitoring brain disorders such as Alzheimer’s disease, brain tumors, epilepsy, and Parkinson’s.

The NeuroLF scanner is a cylindrical helmet into which the patient’s head is placed while seated comfortably. It contains a dense ring of PET detectors closely surrounding the skull, which increases sensitivity to the radiotracer signals emanating from the brain. A patient is first injected with a PET tracer (e.g. a radio-labeled glucose or amyloid-binding molecule), and then the NeuroLF device captures the gamma photons to construct high-resolution images of brain metabolism or pathology. The system’s compact design requires only minimal shielding and no special room, unlike full-size PET/CTs. It also shortens scan times by focusing solely on the brain. Clinically, images from NeuroLF allow doctors to see patterns like amyloid plaque distribution in Alzheimer’s or hypermetabolic foci in epilepsy with clarity comparable to conventional PET, but with a fraction of the equipment footprint.

NeuroLF facilitates wider deployment of brain PET for early and accurate diagnosis. Memory clinics can use it to detect Alzheimer’s changes (amyloid or tau deposition) at early stages, enabling timely treatment in the era of new dementia drugs. Neurologists can employ it for Parkinson’s to differentiate it from other movement disorders via dopaminergic PET imaging. Importantly, because the device is cost-effective and space-saving, smaller hospitals and even outpatient centers can offer PET scans, decentralizing a critical diagnostic that was once limited to large centers. This addresses the growing demand for brain PET as therapies (like amyloid-clearing drugs) require PET confirmation of disease. With regulatory approvals in place and manufacturing scaling up, Positrigo’s dedicated scanner is poised to significantly increase patient access to functional brain imaging, embodying the principle that earlier and more widespread diagnosis leads to better neurological care.